NEW YORK CITY, NY / ACCESS Newswire / October 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AVITA Medical, Inc. ("AVITA" or "the Company") (NASDAQ:RCEL). Investors who purchased AVITA securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/RCEL.
Investigation Details
On October 16, 2025, after market close, AVITA issued a press release called "AVITA Medical Announces CEO Transition." It stated that the Company had "effective immediately," named an Interim Chief Executive Officer, and that in "conjunction with this appointment, Jim Corbett is leaving his positions as CEO and member of the Board." Following this news, AVITA stock fell 25.8% on October 17, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased AVITA securities, you can assist this investigation by visiting the firm’s site: bgandg.com/RCEL. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_469891520/2457/2025-10-29T13:03:07